Patents by Inventor Jorge Plutzky

Jorge Plutzky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Retinaldehyde mimetics and inhibitors of retinaldehyde dehydrogenase I in the treatment of disorders
    Patent number: 9504660
    Abstract: The technology described herein is directed to methods of treating, e.g. obesity by administering retinaldehyde increasing agents.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: November 29, 2016
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Jorge Plutzky, Florian Kiefer
  • Retinaldehyde in the treatment of obesity, diabetes and other conditions
    Patent number: 9078852
    Abstract: The present invention is directed to methods of treating a patient for a disease or condition associated with adipogenesis or insulin resistance by administering a retinaldehyde compound to the patient or a compound that increases endogenous retinaldehyde levels by inhibiting the enzyme retinaldehyde dehydrogenase 1.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: July 14, 2015
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Jorge Plutzky, Ouliana Ziouzenkova
  • RETINALDEHYDE MIMETICS AND INHIBITORS OF RETINALDEHYDE DEHYDROGENASE I IN THE TREATMENT OF DISORDERS
    Publication number: 20140378530
    Abstract: The technology described herein is directed to methods of treating, e.g. obesity by administering retinaldehyde increasing agents.
    Type: Application
    Filed: February 1, 2013
    Publication date: December 25, 2014
    Inventors: Jorge Plutzky, Florian Kiefer
  • COMPOSITIONS AND METHODS FOR MODULATING METABOLISM
    Publication number: 20130252331
    Abstract: The invention provides compositions comprising an effective amount of an agent that inhibits a BET protein (e.g., Brd2, Brd3, Brd4), and methods of using such compositions for treating or preventing metabolic syndrome, obesity, type II diabetes, insulin resistance, and related disorders characterized by undesirable alterations in metabolism or fat accumulation.
    Type: Application
    Filed: May 16, 2011
    Publication date: September 26, 2013
    Inventors: James Elliott Bradner, Jonathan Brown, Jorge Plutzky
  • Retinaldehyde in the Treatment of Obesity, Diabetes and Other Conditions
    Publication number: 20110046234
    Abstract: The present invention is directed to methods of treating a patient for a disease or condition associated with adipogenesis or insulin resistance by administering a retinaldehyde compound to the patient or a compound that increases endogenous retinaldehyde levels by inhibiting the enzyme retinaldehyde dehydrogenase 1.
    Type: Application
    Filed: February 27, 2009
    Publication date: February 24, 2011
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Jorge Plutzky, Ouliana Ziouzenkova
  • Lipoprotein lipase and lipoprotein lipase activators in the treatment of inflammatory conditions
    Publication number: 20050129724
    Abstract: The present invention is directed to compositions which include the enzyme lipoprotein lipase. These compositions may be applied topically to the skin of a person to prevent dryness or treat inflammation. In addition, the invention is directed to the use of fibrates to enhance the activity of lipoprotein lipase. The fibrates may be used orally to treat inflammation or enhance metabolic energy production.
    Type: Application
    Filed: February 4, 2005
    Publication date: June 16, 2005
    Inventors: Jorge Plutzky, Ouliana Ziouzenkova
  • Lipoprotein lipase and lipoprotein lipase activators in the treatment of inflammatory conditions
    Patent number: 6869603
    Abstract: The present invention is directed to compositions which include the enzyme lipoprotein lipase. These compositions may be applied topically to the skin of a person to prevent dryness or treat inflammation. In addition, the invention is directed to the use of fibrates to enhance the activity of lipoprotein lipase. The fibrates may be used orally to treat inflammation or enhance metabolic energy production.
    Type: Grant
    Filed: November 7, 2002
    Date of Patent: March 22, 2005
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Jorge Plutzky, Ouliana Ziouzenkova
  • Lipoprotein lipase and lipoprotein lipase activators in the treatment of inflammatory conditions
    Publication number: 20030129216
    Abstract: The present invention is directed to compositions which include the enzyme lipoprotein lipase. These compositions may be applied topically to the skin of a person to prevent dryness or treat inflammation. In addition, the invention is directed to the use of fibrates to enhance the activity of lipoprotein lipase. The fibrates may be used orally to treat inflammation or enhance metabolic energy production.
    Type: Application
    Filed: November 7, 2002
    Publication date: July 10, 2003
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Jorge Plutzky, Ouliana Ziouzenkova
  • Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
    Publication number: 20020031539
    Abstract: The present invention is directed to certain oxidized forms of retinoic acid and their precursors that have been found to be effective in treating conditions that respond to agents that bind to and activate the human peroxisome proliferator activated receptor-gamma. Specific compounds include oxidized all-trans retinoic acid; oxidized 9-cis retinoic acid; and reduced 4-oxo-retinoic acid. The compounds may be used in treating a number of diseases or conditions including diabetes, low body weight, atherosclerosis, and certain forms of cancer.
    Type: Application
    Filed: August 29, 2001
    Publication date: March 14, 2002
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Jorge Plutzky, Ouliana Ziouzenkova
  • Methods for identifying a tyrosine phosphatase abnormality associated with neoplastic disease
    Patent number: 5536636
    Abstract: The present invention relates to the isolation of genes encoding novel protein tyrosine phosphatases (PTPs) having SH2 domains, the nucleic acid sequences isolated, and the encoded phosphatases. The invention further relates to methods of altering tyrosine phosphatase activities encoded by the novel phosphatases. By altering (i.e., increasing or decreasing) tyrosine phosphatase activity, one can alter megakaryocyte cell function, and thereby alter platelet production. Alteration of the genes is associated with neoplastic disease.
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: July 16, 1996
    Assignees: Beth Israel Hospital, Massachusetts Institute of Technology
    Inventors: Robert M. Freeman, Jr., Jorge Plutzky, Benjamin G. Neel, Robert D. Rosenberg